BEDMINSTER, N.J., Apr 26, 2012 (BUSINESS WIRE) --NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, has been named one of the "Best Places to Work in New Jersey." This is the first time NPS has received this honor, which is awarded every year by NJBIZ, the state's largest business newspaper, to the 100 companies recognized for providing the best work environment throughout New Jersey.
"We are gratified by this recognition of our collaborative culture and dedication to core values - integrity, respect, excellence, personal responsibility, teamwork, and fun," said Francois Nader, M.D., president and chief executive officer of NPS Pharmaceuticals. "I thank and congratulate all of our employees who make NPS such a great place to work and who are committed to bringing innovative new medicines to people with rare disorders."
Employees play a significant role in the rankings, with approximately 75 percent of the evaluation based on a survey that measures employee experience and sentiment. In the 2012 survey, NPS employees praised the company's collaborative, family-like atmosphere, as well as its highly approachable and visible executive team, focus on patients, and practice of recognizing and rewarding achievements. The other 25 percent of the evaluation is based on the company's workplace policies, practices, philosophy, systems and demographics. Data from the surveys and applications, which are submitted by many companies throughout New Jersey, are analyzed by the Best Companies Group to determine the final rankings.
The 100 recognized companies are split into two groups based on size. This year, 52 small/medium companies with 15-249 employees were recognized, including NPS, as were 48 large companies with 250 or more employees.
The rankings were announced at an awards dinner and ceremony on April 25 at the Hilton East Brunswick.
About the Best Places to Work in New Jersey Program
NJBIZ started the Best Places to Work in New Jersey program in 2005 as a way to recognize Garden State companies who contribute to the local economy and workforce. The program is sponsored by Gibbons, P.C. and Novo Nordisk. The program is in partnership with Garden State Council SHRM, The New Jersey State Chamber, Employers Association of New Jersey and the New Jersey Economic Development Authority. Best Companies Group oversaw the application and survey process, and analyzed the data for use in determining the final rankings.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage registration programs. A New Drug Application is undergoing FDA review for Gattex(R)(teduglutide) as a treatment for adult short bowel syndrome (SBS) and a Phase 3 registration study has been completed for Natpara(TM) (recombinant human parathyroid hormone (rhPTH [1-84]) in adult hypoparathyroidism. NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko Kirin, Nycomed, and Janssen Pharmaceuticals, Inc.
SOURCE: NPS Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc.
Susan M. Mesco, 908-450-5516